BriaCell Therapeutics Corp. (BCTX) stock
BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
$3.51+0.21 (+6.36%)
Close on Nov 17, 2026Market cap $30.65MP/E –Yield –
BriaCell Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
BriaCell Therapeutics's operating cash flow for the twelve months ending Jul 31, 2026 was -$28.65M. For fiscal 2026 it was -$28.65M. The highest annual figure on record is -$1.27M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | -$28.65M | – |
| FY2025 | Jul 31, 2025 | -$28.17M | – |
| FY2024 | Jul 31, 2024 | -$24.13M | – |
| FY2023 | Jul 31, 2023 | -$23.74M | – |
| FY2022 | Jul 31, 2022 | -$12.48M | – |
| FY2021 | Jul 31, 2021 | -$7.75M | – |
| FY2020 | Jul 31, 2020 | -$1.27M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | -$5.96M | – |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | -$7.02M | – |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | -$7.97M | – |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | -$7.70M | – |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | -$8.13M | – |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | -$7.16M | – |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | -$5.92M | – |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | -$6.96M | – |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | -$4.04M | – |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | -$5.08M | – |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | -$7.40M | – |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | -$7.61M | – |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | -$10.92M | – |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | -$5.33M | – |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | -$3.95M | – |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | -$3.54M | – |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | -$3.33M | – |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | -$4.82M | – |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | -$2.56M | – |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | -$1.78M | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | -$1.95M | – |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | -$5.59M | – |
See a number that looks wrong?